7.68
전일 마감가:
$7.47
열려 있는:
$7.69
하루 거래량:
1.05M
Relative Volume:
1.30
시가총액:
$545.49M
수익:
-
순이익/손실:
$-119.87M
주가수익비율:
-4.2431
EPS:
-1.81
순현금흐름:
$-109.90M
1주 성능:
-8.13%
1개월 성능:
-23.20%
6개월 성능:
-21.71%
1년 성능:
-25.58%
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
ORIC을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ORIC
Oric Pharmaceuticals Inc
|
7.68 | 545.49M | 0 | -119.87M | -109.90M | -1.81 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-10-31 | 개시 | Wells Fargo | Overweight |
2024-09-06 | 개시 | Stifel | Buy |
2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
2023-09-22 | 개시 | Wedbush | Outperform |
2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
2022-07-18 | 재개 | Oppenheimer | Perform |
2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-08-13 | 개시 | Robert W. Baird | Outperform |
2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
2020-08-03 | 개시 | H.C. Wainwright | Buy |
2020-05-19 | 개시 | Citigroup | Neutral |
2020-05-19 | 개시 | Guggenheim | Buy |
2020-05-19 | 개시 | JP Morgan | Overweight |
2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
Wedbush Expects Reduced Earnings for ORIC Pharmaceuticals - MarketBeat
Wedbush Predicts Weaker Earnings for ORIC Pharmaceuticals - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up on Earnings Beat - MarketBeat
ORIC Pharmaceuticals Inc (ORIC) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 5.6%Should You Sell? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Oric Pharmaceuticals, Inc. SEC 10-K Report - TradingView
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates - GlobeNewswire
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and ... - The Bakersfield Californian
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 6.4%Should You Sell? - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpWhat's Next? - MarketBeat
ORIC Pharmaceuticals' (ORIC) "Buy" Rating Reiterated at Guggenheim - MarketBeat
ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright - MSN
Oric recent weakness a buying opportunity, says JPMorgan - MSN
ORIC’s price-to-book ratio: An indicator of the company’s performance - US Post News
Jones Trading maintains Buy on ORIC, $17 target on positive data - MSN
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up – What’s Next? - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Buy” Rating at Guggenheim - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 14.7%Time to Buy? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Given New $21.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Oric Pharmaceuticals: Promising Trials and Strong Financials Justify Buy Rating - TipRanks
ORIC Pharmaceuticals shares surge on potential data leak - MSN
Optimistic Buy Rating for Oric Pharmaceuticals Driven by Promising Data and Favorable Risk/Reward Profile - TipRanks
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.29 Consensus Price Target from Analysts - MarketBeat
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for ORIC Pharmaceuticals (NASDAQ:ORIC) Stock - Armenian Reporter
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 15.6%Here's Why - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharma's Latest Talent Investment: Strategic Equity Awards Unveiled - StockTitan
There is no doubt that ORIC Pharmaceuticals Inc (ORIC) ticks all the boxes. - SETE News
ORIC Pharmaceuticals Inc (ORIC) may enjoy gains as insiders got busy in the recent days - Knox Daily
Daily Market Movement: ORIC Pharmaceuticals Inc (ORIC) Sees a -2.59 Decrease, Closing at 10.15 - The Dwinnex
ORIC Pharmaceuticals Inc (ORIC)’s stock chart: A technical perspective - US Post News
Citi maintains ORIC stock Buy rating, $13 target ahead of PFE data - MSN
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 15.6% – Still a Buy? - Armenian Reporter
ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data - Seeking Alpha
SG Americas Securities LLC Sells 3,256 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
JPMorgan Chase & Co. Increases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
ORIC Pharmaceuticals to Present at Three Major Healthcare Investor Conferences - StockTitan
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 5.6%Should You Buy? - MarketBeat
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oric Pharmaceuticals Inc 주식 (ORIC) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Piscitelli Dominic | Chief Financial Officer |
Dec 16 '24 |
Sale |
8.28 |
8,851 |
73,298 |
106,764 |
Multani Pratik S | Chief Medical Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
55,615 |
Multani Pratik S | Chief Medical Officer |
Dec 16 '24 |
Sale |
8.28 |
8,850 |
73,293 |
46,765 |
Chacko Jacob | PRESIDENT AND CEO |
Dec 15 '24 |
Option Exercise |
0.00 |
67,000 |
0 |
803,308 |
Chacko Jacob | PRESIDENT AND CEO |
Dec 16 '24 |
Sale |
8.28 |
24,660 |
204,214 |
778,648 |
자본화:
|
볼륨(24시간):